$3,06
▼ $-0,09
(-2,86%)
Vol. 4.7M
5
Punteggio di Qualità
fail
Ricavi ✗
Utile netto ✗
>IPO ✗
Cap. mercato
$524.8M
ROE
-60,2%
Margine
-4071,2%
D/E
0,65
Beta
2,15
52W
$2–$6
Consenso Wall Street
15 analisti · Apr 20263
Acquisto forte
10
Compra
2
Mantieni
0
Vendi
0
Vendita forte
86,7%
Rating Compra
Grafico dei Prezzi
Titoli simili
Utili
Tasso di battuta: 40,0%
Prossimo report
Mag 11, 2026
Stima EPS: $-0,20
| Trimestre | EPS Stimato | EPS Effettivo | Sorpresa |
|---|---|---|---|
| Mar 2026 | $-0,20 | — | — |
| Dic 2025 | $-0,20 | $-0,20 | $0,00 |
| Set 2025 | $-0,22 | $-0,20 | +$0,02 |
| Giu 2025 | $-0,22 | $-0,24 | $-0,02 |
Ricavi e utili trimestrali
| Trimestre | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… |
|---|---|---|---|---|---|
| Ricavi | $1.7M | $665K | $1.2M | $593K | $378K |
| Utile netto | -$27.4M | -$29.0M | -$26.3M | -$30.6M | -$28.7M |
Trend fondamentali
| Metrica | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -60.2% | -60.2% | -60.2% | -60.2% | -60.2% | -60.2% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -5155.0% | -2737.9% | -2737.9% | -2737.9% | -4071.2% | -4071.2% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 1.24 | 1.24 | 1.24 | 1.24 | 0.65 | 0.65 |
| Current Ratio | 4.39 | 4.39 | 4.39 | 4.39 | 5.89 | 5.89 |
Rapporti chiave
ROA (TTM)
-50,9%
P/S (TTM)
186,43
P/B
1,7
EPS (TTM)
$-0,90
CF/Share
$-1,01
Crescita ricavi 3A
-1,8%
52W High
$6,33
52W Low
$2,01
$2,01
Intervallo 52 settimane
$6,33
Salute finanziaria
Flusso di cassa libero
-$26.0M
Debito netto
-$3.3M
Liquidità
$9.5M
Debito totale
$6.2M
Aggiornato al Set 30, 2025
Як ABSI виглядає на тлі конкурентів у Biotechnology?
Група порівняння: Micro-cap Biotechnology (All) · 528 компаній
Оцінка ABSI vs аналоги Biotechnology
P/E
—
▼
0%
sotto
peer
(18,8)
vs Peer
vs Settore
Sottovalutato
P/S
186,4
▲
1351%
sopra
peer
(12,9)
vs Peer
vs Settore
Più costoso
P/B
1,7
▼
32%
sotto
peer
(2,5)
vs Peer
vs Settore
Più costoso
Дивідендна дохідність
—
▼
0%
sotto
peer
(0,0%)
vs Peer
vs Settore
Rendimento basso
Прибутковість ABSI vs аналоги Biotechnology
ROE
-60,2%
▲
11%
sopra
peer
(-67,3%)
vs Peer
vs Settore
In linea
Net margin
-4071,2%
▼
1320%
sotto
peer
(-286,8%)
vs Peer
vs Settore
Debole
Валова маржа
—
▼
0%
sotto
peer
(78,6%)
vs Peer
vs Settore
In linea
ROA
-50,9%
▼
9%
sotto
peer
(-46,7%)
vs Peer
vs Settore
In linea
Фінансове здоровʼя ABSI vs аналоги Biotechnology
D/E ratio
0,7
▼
0%
sotto
peer
(0,0)
vs Peer
vs Settore
In linea
Поточна ліквідність
5,9
▲
33%
sopra
peer
(4,4)
vs Peer
vs Settore
Sotto media
Beta
2,2
▲
122%
sopra
peer
(1,0)
vs Peer
vs Settore
Più volatile
Радар фундаменталів ABSI
ABSI
Mediana peer
Industria
ABSI прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
ABSI vs аналоги: ключові метрики
Attività insider
NeutralAcquisti
0
Vendite
0
BUSCH ANDREAS
Officer · Mar 12
100000 shs
MCCLAIN SEAN
Chief Executive Officer · Mar 02
406200 shs
MCCLAIN SEAN
Chief Executive Officer · Mar 02
406200 shs
BEDRICK TODD
Officer · Mar 02
49600 shs
BEDRICK TODD
Officer · Mar 02
49600 shs
JONASSON ZACHARIAH
Chief Financial Officer · Mar 02
135400 shs
JONASSON ZACHARIAH
Chairman of the Board · Mar 02
135400 shs
WALKER SHELBY J
Officer · Mar 02
90300 shs
WALKER SHELBY J
Officer · Mar 02
90300 shs
PANGALOS MENELAS N
Director · Mar 02
5800 shs
Ultimo 90 giorni
Principali azionisti
Top 5: 41,52%FMR, LLC
14,88%
$62.2M
ARK Investment Management, …
8,35%
$34.9M
Blackrock Inc.
7,54%
$31.5M
Redmile Group, LLC
5,49%
$22.9M
Vanguard Group Inc
5,26%
$22.0M
Aggiornato al Dic 31, 2025
Ultime notizie
Nessuna notizia correlata ancora